Ligand validation:4F4S

EFO: Oligomycin A

EFO is a Ligand Of Interest in 4F4S designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
4F4S_EFO_B_102	57%	19%	0.128	0.903	2.19	1.31	12	9	1	0	100%	1
4F4S_EFO_O_101	47%	18%	0.142	0.882	2.35	1.25	11	9	1	0	100%	1
4F4S_EFO_E_101	41%	18%	0.161	0.875	2.3	1.29	14	8	0	0	100%	1
4F4S_EFO_K_101	7%	14%	0.331	0.796	2.42	1.49	12	10	5	0	100%	1
4F4S_EFO_M_101	7%	13%	0.267	0.729	2.42	1.55	11	9	1	0	100%	1
4F4S_EFO_K_102	5%	15%	0.26	0.679	2.34	1.5	14	10	3	0	100%	1
4F4S_EFO_B_101	1%	15%	0.413	0.542	2.42	1.35	14	10	0	0	100%	1
5BPS_EFO_B_102	49%	20%	0.134	0.878	2.23	1.19	16	7	0	0	100%	1
3WGV_EFO_A_2015	46%	3%	0.144	0.879	2.21	3.79	20	25	0	0	100%	1
4WQ0_EFO_A_502	2%	14%	0.406	0.664	1.43	2.37	4	25	2	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.